Dr. Spector Discusses the Systemic Nature of Cancer

Neil L. Spector, MD
Published: Tuesday, Apr 10, 2012

Neil L. Spector, MD, co-director, Experimental Therapeutics, Duke Cancer Institute, Duke University Medical Center, Durham, North Carolina, explains that specialists have a tendency to over simplify cancer, which is a very systemic disease that varies depending on the location and tumor type.

The cancer cells unique gene mutations while the area around the tumor and metastatic extensions may carry very different molecular characteristics. Spector describes it as "the seed versus the soil," where the tumor is the seed and the soil is the surrounding microenvironment.

The molecular differences observed between the tumor and microenvironment may lead to treatment resistance. These differences are further echoed by those seen in the primary tumor and metastatic sites, which are each molecularly unique. The varying molecular profile witnessed systemically can greatly affect the treatment paradigm.

Each of these molecular variations makes cancer extremely complex. Determining the systemic differences using molecular analysis will help researchers develop therapies and combinations of therapies that can have a dramatic break-through effect on the treatment of cancer.

Neil L. Spector, MD, co-director, Experimental Therapeutics, Duke Cancer Institute, Duke University Medical Center, Durham, North Carolina, explains that specialists have a tendency to over simplify cancer, which is a very systemic disease that varies depending on the location and tumor type.

The cancer cells unique gene mutations while the area around the tumor and metastatic extensions may carry very different molecular characteristics. Spector describes it as "the seed versus the soil," where the tumor is the seed and the soil is the surrounding microenvironment.

The molecular differences observed between the tumor and microenvironment may lead to treatment resistance. These differences are further echoed by those seen in the primary tumor and metastatic sites, which are each molecularly unique. The varying molecular profile witnessed systemically can greatly affect the treatment paradigm.

Each of these molecular variations makes cancer extremely complex. Determining the systemic differences using molecular analysis will help researchers develop therapies and combinations of therapies that can have a dramatic break-through effect on the treatment of cancer.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x